Tonix Pharmaceuticals Holding Corp. (TNXP) stock declined over -1.33%, trading at $0.18 on NASDAQ, down from the previous close of $0.19. The stock opened at $0.19, fluctuating between $0.18 and $0.19 in the recent session.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Employees | 103 |
Beta | 2.08 |
Sales or Revenue | $7.77M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) stock price is $0.18 in the last trading session. During the trading session, TNXP stock reached the peak price of $0.19 while $0.18 was the lowest point it dropped to. The percentage change in TNXP stock occurred in the recent session was -1.33% while the dollar amount for the price change in TNXP stock was -$0.00.
The NASDAQ listed TNXP is part of Biotechnology industry that operates in the broader Healthcare sector. Tonix Pharmaceuticals Holding Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Siobhan Fogarty B.Sc., M.Sc.
Executive Vice President of Product Devel.
Dr. Darryl Rideout Ph.D.
Executive Vice President of Experimental Chemistry
Mr. Bradley Saenger CPA, CPA
Chief Financial Officer & Treasurer
Mrs. Jessica Edgar Morris
Chief Operating Officer
Dr. Gregory M. Sullivan M.D.
Chief Medical Officer & Sec.
Dr. Herbert W. Harris M.D., Ph.D.
Executive Vice President of Translational Medicine
Dr. Bruce L. Daugherty M.B.A., Ph.D.
Executive Vice President of Research
Dr. Daniel J. Clauw M.D.
Consultant
Dr. Sina Bavari Ph.D.
Executive Vice President of Infectious Disease R&D
Dr. Zeil Rosenberg M.D., M.P.H.
Executive Vice President of Medical
Mr. Bradley Saenger C.P.A., CPA
Chief Financial Officer & Treasurer
Dr. Seth Lederman M.D.
Co-Founder, Pres, Chief Executive Officer & Chairman
TNXP's closing price is 56.17% higher than its 52-week low of $0.12 where as its distance from 52-week high of $22.08 is -99.15%.
Number of TNXP employees currently stands at 103.
Official Website of TNXP is: https://www.tonixpharma.com
TNXP could be contacted at phone 862 799 8599 and can also be accessed through its website. TNXP operates from 26 Main Street, Chatham, NJ 07928, United States.
TNXP stock volume for the day was 4.4M shares. The average number of TNXP shares traded daily for last 3 months was 34.42M.
The market value of TNXP currently stands at $34.56M with its latest stock price at $0.18 and 186.89M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com